News for Cybin Inc. (CYBN.NE)

Lucid Capital has begun coverage on Cybin (CYBN), giving it a Buy rating and setting a price target of $106. The analyst sees potential in Cybin's work on new f

Cybin, trading under the ticker CYBN, has been granted a U.S. patent, numbered 12,318,477, by the United States Patent and Trademark Office. This patent support

Cybin Inc. (CYBN) CEO Doug Drysdale to participate in a Water Tower Research Fireside Chat on May 29, 2025. Discussion to cover CYB003 Phase 3 program,

Cybin's collaboration with Thermo Fisher signifies a critical step in advancing its CYB003 program. Analysts predict a substantial potential upside for

Cybin Inc. (CYBN) CEO Doug Drysdale to discuss innovative treatments at the Alliance Global Partners Healthcare Showcase on May 21, 2025. Focus on Cybin

**media[619276]**

Doug Drysdale, CEO of Cybin Inc. (CYBN), to speak at the 28th Annual Milken Institute Global Conference. Panel discussion titled ”œThe Global Landscape

Cybin Inc. (CYBN) has strengthened its strategic alliances, now partnering with a total of 18 clinical sites to support its ongoing multinational Phase 3 trial

Cybin Inc. (CYBN) partners with Osmind to enhance commercial readiness for its psychiatric treatment programs. The collaboration taps into Osmind's netw

Psychedelic-assisted therapy is on the rise, and a new report confirms the rate of expansion of the psychedelic mushrooms market.

**media[560484]**

The heavy selling pressure might have exhausted for Cybin Inc. (CYBN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Cybin Inc.

In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of "alternate reality." One class of hallucinogenic substances that can produce unusual states of...

The consensus price target hints at a 988.7% upside potential for Cybin Inc. (CYBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Significant Transaction in Cybin Inc On December 31, 2024, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a notable transaction involving Cybin Inc, a

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

– Launched strategic clinical site partnerships to accelerate PARADIGM, a multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of ma…

The average of price targets set by Wall Street analysts indicates a potential upside of 952.2% in Cybin Inc. (CYBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.